Drug Development ProgressPoseida presented positive preliminary non-human primate data from the P-KLKB1-101 program, which reinforce confidence in the drug’s therapeutic potential.
Financial PerformancePoseida’s financial results for the first quarter outperformed consensus estimates, with higher revenues and a lower net loss per share than expected.
Strategic PartnershipsPoseida announced a second partnership with Astellas Pharma focused on developing novel off-the-shelf cell therapies for solid tumors, bringing in non-dilutive funding and serving as a strong vote of confidence in its allogeneic CAR-T platform.